Medical Engineering and Physics 74 (2019) 82–88

Contents lists available at ScienceDirect

Medical Engineering and Physics

journal homepage: www.elsevier.com/locate/medengphy

# Concurrent agreement between ActiGraph® and activPAL® in measuring moderate to vigorous intensity physical activity for adults

Long F.R. Lee, Philippa M. Dall*

*School of Health & Life Sciences, Glasgow Caledonian University, Cowcaddens Road, Glasgow G4 0BA, United Kingdom*

ARTICLE INFO

*Article history:*
Received 26 April 2018
Revised 17 May 2019
Accepted 20 September 2019

*Keywords:*
Physical activity
Exercise
Objective measurement
Body-worn sensor
Accelerometer
Validation

ABSTRACT

This study aimed to assess the ability of the activPAL® monitor (commonly used for measuring Sedentary Behaviour (SB), sitting or reclining with low energy expenditure while awake) to measure moderate to vigorous physical activity (MVPA), by assessing its agreement with the concurrent measurement by ActiGraph® monitor (commonly used for measuring MVPA) to identify if a single monitor could be used to measure both MVPA and SB. A convenience sample of 24 adults (79% female; aged 23–60) wore an ActiGraph® GT3X+ and an activPAL3® concurrently for one day during free-living activities. Time spent in MVPA was calculated as an outcome measure using published methods (ActiGraph®, $n=6$; activPAL® $n=4$). Agreement was assessed between pairs of outcomes using the Bland & Altman method. Participants engaged in between 60 and 145 min of MVPA. The activPAL® method summing time walking with a cadence ≥100 steps/min underestimated MVPA compared with the ActiGraph® but had the lowest aggregate bias (−16 min). Other activPAL® methods, based on acceleration counts and the embedded MET algorithm, overestimated MVPA compared to the ActiGraph®. The study was limited by the lack of activPAL® acceleration count methods developed for adults. With the recommended methods, the activPAL® could be suitable for use as a single monitor to measure both SB and MVPA.



## 1. Introduction[1]

Lack of physical activity (PA) is a leading risk factor for mortality worldwide. A third (31%) of adults are physically inactive [1] causing approximately 3.2 million deaths every year [2,3] and representing a substantial global financial burden [4]. Engaging in a combination of moderate and vigorous PA (MVPA; ≥3 METs (metabolic equivalents) [5]) provides benefits for health, fitness and body composition [6] and forms a key element in worldwide PA guidelines. More recently, sedentary behaviour (SB; defined as sitting or reclining while awake [7]) has been investigated as a behaviour distinct from lack of physical activity (physical inactivity). SB has a detrimental effect on health, mortality and cardiometabolic disease [8,9], which may be independent of PA. Measurement of both PA and SB is required to monitor population levels (surveillance), and to assess the effects of epidemiological and intervention studies [10]. Long-term (e.g. 1 week) objective measurement of both PA and SB during daily life is available through use of body-worn sensors. However, a range of different monitors are available, differing by wear location and monitor output, with relative strengths and weaknesses [11–13]. This can make appropriate monitor selection for research difficult and may compromise direct comparison of outcome measures from studies using different monitors.

The most widely used accelerometer to measure PA for research is the ActiGraph® (ActiGraph® LLC, Pensacola, FL) accelerometer [14]. Usually worn at the hip, and sampled at 30–100 Hz, the output is expressed as 'counts' (a proprietary value related to acceleration) aggregated over a user-specified 'epoch' (time interval) [15]. Acceleration counts are translated into meaningful output (e.g.

* Corresponding author.
*E-mail address:* philppa.dall@gcu.ac.uk (P.M. Dall).

[1] AG56: method of calculating MVPA from the ActiGraph monitor using a VM threshold of 56 counts per 1s epoch; AG1952: method of calculating MVPA from the ActiGraph monitor using a VT threshold of 1952 counts per minute (Freedson cut-points); AG2000 method of calculating MVPA from the ActiGraph monitor using a V T threshold of 2000 counts per minute (167 counts per 5s epoch); AG2020: method of calculating MVPA from the ActiGraph monitor using a VT threshold of 2020 counts per minute; AG2960 method of calculating MVPA from the ActiGraph monitor using a VM threshold of 2960 counts per minute; AG3208 method of calculating MVPA from the ActiGraph monitor using a VM threshold of 3208 counts per minute; aP3: method of calculating MVPA from the activPAL monitor using a value of 3METs from the embedded MET algorithm; aP100: method of calculating MVPA from the activPAL using 100 steps/minute cadence; aP1418: method of calculating MVPA from the activPAL using an acceleration threshold of 1418; aP2997: method of calculating MVPA from the activPAL using an acceleration threshold of 2997; LOA: limits of agreement; MET: metabolic equivalent; MVPA: moderate to vigorous physical activity; PA: physical activity; SB: sedentary behaviour; VM: vector magnitude; VT: vertical axis.

https://doi.org/10.1016/j.medengphy.2019.09.018
1350-4533/

time spent in MVPA) using 'cut-points', which are threshold values derived from calibration and validation studies against the corresponding MET value for the PA being performed [15]. Whilst the ActiGraph® is acknowledged as an appropriate monitor to measure time spent in MVPA, the selection of cut-point is dependent on epoch length [16], and there is disagreement as to which are most accurate [15]. For measurement of SB, the ActiGraph® uses a low count cut-point to distinguish sitting from light PA. Worn on the hip, the ActiGraph® is unable to measure the posture of sitting, instead measuring a lack of movement, which may misclassify some standing activities as SB, e.g. washing up [17].

An alternative monitor option, growing in popularity, is the activPAL® (PAL Technologies Ltd, Glasgow, UK). This accelerometer-based monitor is worn on the anterior thigh and uses thigh inclination to distinguish between the postures of sitting and standing [18]. The activPAL® has a sensitivity of 98% in adults for measuring SB against observation [19], and is regarded as the gold standard for measuring time spent in SB [20]. Whilst the activPAL® also distinguishes between time spent standing and walking, with an accuracy of approximately 98% [21], time spent in MVPA is not one of its standard outputs. Options for converting activPAL® output into time spent in MVPA are varied and have only limited validation. They include, use of the integral (embedded) activPAL® output of METs generated from standard values for the posture or cadence of walking [22], use of cadence of walking to identify MVPA walking bouts [23] or use of the raw acceleration output to generate cut-points for MVPA [24].

Given the complex interplay between SB, PA and health [25], the simultaneous measurement of both SB and PA has become important in public health research. Many researchers opt to ask their participants to wear two monitors, one optimised to assess MVPA (e.g. the ActiGraph®) and one optimised to measure SB (e.g. the activPAL®). However, having a single instrument that is valid and reliable to measure both SB and MVPA would be more convenient and cost efficient [16,26,27].

Previous studies comparing concurrent measures of both the ActiGraph® and the activPAL® to a criterion measure (direct/video observation or a wearable camera), have been conducted only for the assessment of time spent in SB [20,28,29]. In each case, the activPAL® provided a more accurate measure of time spent in SB (compared to the criterion) than the ActiGraph®. For example, the Youden Index (combined effect of sensitivity and specificity) was 92% for the activPAL® compared to 75% for the ActiGraph® [28]. The activPAL® is recommended for measurement of SB [20,28], and is frequently used as the referent standard to measure SB in studies assessing concurrent validity of the ActiGraph® [e.g. 16,30,31]. The concurrent agreement of the ActiGraph® and the activPAL® to measure MVPA has not been evaluated in free-living studies (with or without a criterion measure).

The inherent inability of an ActiGraph® worn at the hip to distinguish between the postures of sitting and standing [17], means that it may not be suitable for use as a single monitor to assess MVPA and SB. Therefore, the current study aimed to explore the ability of the activPAL® to measure MVPA, by assessing the concurrent agreement of published methods to classify MVPA using the activPAL® and the ActiGraph® in a free-living environment.

## 2. Methods

### 2.1. Study design

In this cross-sectional study, participants wore an ActiGraph® and an activPAL® monitor concurrently during one day of free-living activity, to assess the agreement in time spent in MVPA measured by the two monitors.

### 2.2. Participants

A convenience sample was recruited via email invitations to staff and students from the School of Health and Life Sciences, Glasgow Caledonian University. Participants were adults, aged between 18 and 65, without any upper- or lower- limb functional impairment, neurological conditions affecting upper- or lower- limb function or a known allergy to the material used to attach the monitors. Ethical approval was provided by the School of Health at Glasgow Caledonian University ethics committee, and informed consent was obtained from all participants before data collection.

### 2.3. Protocol

Participants were met on Day 0 by a researcher, and answered self-reported demographic questions (age, gender, height and weight). Two monitors (activPAL3®; ActiGraph® GT3X) were attached to the participant, and a diary to record wear times for the monitors was provided. Participants wore the monitors on Day1 (including overnight for the activPAL®), and recorded sleep times and time for monitor attachment/removal in the diary. Participants met the researcher on Day 2 to return the monitors.

Participants wore an activPAL3® (27 g; $3.8 \times 3.7 \times 1.8$ cm), programmed for immediate start and set to record for 3 days. The activPAL® was worn on the midline on the anterior aspect of the thigh, at the midpoint between knee and hip joint, and was attached by the researcher using double sided hypoallergenic adhesive pads (PAL stickies, PAL technologies, Glasgow, UK). Participants were instructed to wear the monitor including overnight, but the monitor was not waterproofed and was removed for water-based activities.

Participants wore an ActiGraph® GT3X (15 g; $5.3 \times 3.5 \times 0.7$ cm), programmed to record data at 80 Hz. ActiGraph® monitors were worn on the axillary line of right iliac crest using an elastic strap provided by the manufacturer. Participants attached the monitor themselves and monitors were not worn overnight or during water-based activities.

### 2.4. Data processing

Comparisons between the outputs of the two monitors were made within subjects using the data recorded on Day 1 in the period when both monitors were worn. The range of time was selected according to the attachment and removal times recorded in the diary.

All the methods used in this study to classify MVPA have been previously published (Table 1). Four methods for classifying MVPA using the activPAL® monitor were included, using three different types of monitor output (activity count from the raw acceleration data; MET values generated from activPAL's® embedded formula; cadence of walking events). The two activity count methods were not developed for an adult population, but since there were no other methods that used the activPAL's® activity count, they were included in the current study. Therefore, ActiGraph® methods developed for both adult and non-adult populations were also selected for inclusion. As there is no agreement as to which ActiGraph® cut-point is best, six published ActiGraph® methods to derive MVPA were included in the current study.

ActivPAL® data were downloaded using the activPAL® professional software (version 6.4.1). MVPA was derived according to published methods, using the specified activPAL® output. For the two methods deriving MVPA from the activPAL® raw acceleration (count) data [24,27], the 15 s epoch output was used. Both of these cut-points were developed using uniaxial activPAL® monitors, therefore in this study only activity counts in the channel 1 ($x$-axis), the common channel shared by activPAL® (uni-axial) and

**Table 1**
Characteristics of previously published methods to categorise time spent in MVPA (as used in the current study).

| Reference | Monitor | Acronym | output | axes | Cut-point value | Epoch | Development Population |
|---|---|---|---|---|---|---|---|
| [22] | activPAL® | **aP3** | MET | – | 2.99 | 1s | Adults |
| [35–37] | | **aP100** | cadence | – | 100 | per event | Adults |
| [27] | | **aP1418** | activity counts | thigh | 1418 | 15s | Children |
| [24] | | **aP2997** | activity counts | thigh | 2997 | 15s | Adolescents |
| [43] | ActiGraph® | **AG1952** | activity counts | VT | 1952 | 60s | Adults |
| [44] | | **AG2000** | activity counts | VT | 166.7[1] | 5s | Children |
| [45] | | **AG2020** | activity counts | VT | 2020 | 60s | Adults |
| [42] | | **AG56** | activity counts | VM | 56 | 1s | Children |
| [41] | | **AG2690** | activity counts | VM | 2690 | 60s | Adults |
| [46] | | **AG3208** | activity counts | VM | 3208 | 60s | Adults |

MET: Metabolic equivalent; MVPA: moderate to vigorous physical activity; VT vertical axis; VM: vector magnitude. Time spent in MVPA reported as mean ± standard deviation. [1] Threshold values calculated as 2000 counts per minute/12 to provide value for 5 s epochs.

activPAL3® (tri-axial) monitors [32], were used to calculate MVPA. Each 15 s epoch was categorised as MVPA if the activity count was above the specified cut-point (Table 1). The sum of duration of 15 s epochs categorised as MVPA was used to derive outcome measures of total time spent in MVPA.

The PAL embedded algorithm to calculate METs assigns METs values based on activity classification (sit/lie: 1.2METs; standing: 1.4MET; walking: varying linearly with cadence, walking at 120 steps/minute is 4METs [33]). For the method deriving MVPA from the embedded MET algorithm [22], data were first reprocessed to change the embedded MET algorithm so that data categorised as standing was classified as 1.5METs. Data was exported as an event file and was then extrapolated in to 1 s epochs using an R package (*activpalProcessing*) [34]. The 1 s epochs were categorised as MVPA if the METs calculated by the embedded activPAL® algorithm were >2.99METs. The sum of duration of 1 s epochs categorised as MVPA was used to derive outcome measures of total time spent in MVPA.

For the method using cadence, the event output was used to calculate MVPA. Each event is defined as a continuous period of categorised activity [18]. Although a cadence of 100 steps/minutes has been advocated as a cut-point for moderate physical activity when walking (derived from validation studies [35–37]), the use of this cut-point as a measure of MVPA in activPAL® derived walking had not been validated. An excel macro (HSC PAL analysis software V2.21) was used to firstly create walking events from consecutive stepping events and calculate average cadence (number of steps in the event/event duration), and secondly to separate output into sedentary, standing and walking events. Walking events with an average cadence ≥100 steps/min were categorised as MVPA, and total time spent in MVPA was calculated as the sum of the duration of all such walking events.

ActiGraph® data was downloaded using ActiLife software (version 5.10.0), and was exported in 1 s epochs. The six published ActiGraph® cut-points selected for this study, varied in the epoch length over which counts were aggregated, the count cut-point used to define MVPA and the monitor axes used to provide the count value (vertical axis only (VT) or vector magnitude (VM)). Specific values for these characteristics for each method can be found in Table 1. The vector magnitude (VM) was calculated from three axes (square root of the sum of squares of each axis [38]). Different epochs were subsequently created by summing up the 1 s epochs on either vector magnitude (VM) or vertical axis (VT). The sum of duration of appropriate epochs classed as MVPA (if greater than the cut-points for VT or VM, as appropriate) for each method was used to derive outcomes measures (one per method) of total time spent in MVPA.

### 2.5. Statistical analysis

The outcome measures were total time spent in MVPA, calculated using four different activPAL® methods and six different ActiGraph® methods, reported as mean and standard deviation. The Bland–Altman method was used to assess agreement between each pair of methods to derive MVPA. Data are presented as mean and standard deviation of bias, and 95% Limits of Agreement (LOA; mean bias ±1.96 standard deviation), Bland–Altman diagrams for selected pairs are presented in the supplemental material. To show the direction of bias, absolute difference was not used to calculate agreement.

## 3. Results

Twenty-five adults participated in this study. One set of activPAL® data was missing due to technical issues (data did not download), therefore data from twenty-four individuals were included in this analysis. Participants were mostly women ($n = 19$; 79%), with an average age of 38±11 (23–60) years. Four participants did not disclose their height and/or weight, and the remaining participants were on average overweight (mean BMI 27.92±2.79 $kgm^{-2}$).

The mean time spent in MVPA ranged between 60 and 145 min (Table 2), with both the lowest and the highest times reported by activPAL® methods. The six ActiGraph® methods were more comparable, with mean time spent in MVPA ranging from 64 min to 94 min, whilst those that used the vertical axis only (VT) were spread across only 12 min (between 64 and 76 min). Grouping methods of defining MVPA by development population (refer to Table 1), the four methods developed for children and adolescents reported higher average time spent in MVPA (102±41 min) than methods developed for adults (73±37 min).

In general, the cadence-based activPAL® method (aP100) tended to underestimate MVPA compared to the ActiGraph®, whereas the other methods (based on METs and activity counts) tended to overestimate MVPA relative to ActiGraph® methods (Table 2). As expected, the activity count methods with the lower cut-points categorised more time as MVPA than those with higher cut-points. Amongst all activPAL® methods, aP100 had the smallest average bias (−16±28 min) against all ActiGraph® cut-points, compared with aP3 (17±27 min), aP2997 (18±28 min), and aP1418 (69±44 min). There were several specific pairs of methods with a small bias (Fig. 1), the smallest bias was between aP3 and AG56 and between aP2997 and AG56. However, as bias was calculated on signed (as opposed to absolute) data, this should be treated with caution due to the large 95% LOA. The smallest 95% LOA (range <90 min) were between the cadence-based activPAL method (aP100) and the ActiGraph® methods based on the vertical axis (AG1952, AG2000, AG2020). The aP1418 methods had the largest bias (50–80 min) coupled with large ranges between the 95% LOA (160 to 180 min).

In general, methods using vector magnitude reported more time spent in MVPA than those using the vertical axis. The ActiGraph® methods based on the vertical axis agreed relatively closely with

**Table 2**
Mean time spent in MVPA, bias and 95% limits of agreement for MVPA between pairs of activPAL® and ActiGraph® methods.

| | | activPAL® | | | | |
|---|---|---|---|---|---|---|
| | | method | METs | Cadence | Activity counts | |
| | | acronym [Mean ± SD] | aP3 [93 ± 41] | aP100 [60 ± 32] | aP1418 [145 ± 58] | aP2997 [93 ± 43] |
| ActiGraph® axes | acronym | [Mean ± SD] | Bias (95% LOA) | Bias (95% LOA) | Bias (95% LOA) | Bias (95% LOA) |
| VT | AG1952 | [66± 36] | 27 ± 23 (−18 to 72) | −6 ± 22 (−50 to 37) | 79 ± 43 (−4 to 163) | 27 ± 25 (−22 to 77) |
| | AG2000 | [76± 31] | 17 ± 24 (−30 to 64) | −16 ± 23 (−61 to 28) | 69 ± 42 (−14 to 152) | 17 ± 26 (−34 to 68) |
| | AG2020 | [64 ± 35] | 29 ± 23 (−16 to 74) | −4 ± 21 (−46 to 38) | 81 ± 43 (−3 to 166) | 29 ± 26 (−21 to 80) |
| VM | AG56 | [94 ± 30] | −1 ± 30 (−61 to 58) | −35 ± 32 (−97 to 28) | 51 ± 44 (−35 to 137) | −1 ± 29 (−58 to 56) |
| | AG2690 | [87 ± 41] | 6 ± 32 (−56 to 69) | −27 ± 36 (−98 to 43) | 58 ± 45 (−31 to 147) | 7 ± 31 (−55 to 68) |
| | AG3208 | [67 ± 36] | 26 ± 30 (−32 to 84) | −8 ± 31 (−68 to 52) | 78 ± 46 (−13 to 168) | 26 ± 28 (−30 to 82) |

LOA: limits of agreement; METs: metabolic equivalent; MVPA: moderate-vigorous physical activity; SD: standard deviation; VT: vertical axis; VM: vector magnitude. Data presented as bias (activPAL® method – ActiGraph® method) mean ± standard deviation, and 95% LOA.




**Fig. 1.** Bland–Altman plots of mean bias in time spent in MVPA and 95% limits of agreement for time spent in MVPA measured by (a) aP3-AG56 (b) aP2997 - AG56 (c) aP100-AG2020 (d) aP100-AG1952 (e) AG1952-AG2020 (f) aP3-aP2997.

each other (bias <12 min, range of 95%LOA <40 min, Table 3). In particular, AG1952 and AG2020 (Fig. 1e) were the most comparable methods with bias of −2 min and 95% LOA from −6 to 2 min. These two methods differed only in the activity count cut-point (~3%), whilst the epoch and axis used were the same. Two of the vector magnitude methods (AG56 and AG2690), had reasonable agreement with each other but not with the three vertical axis methods. However, the vector magnitude-based AG3208 appeared to agree better with the three VT methods than the other two VM methods.

In contrast to ActiGraph® methods, the four ActivPAL® methods showed little comparability with each other (Table 4). For

**Table 3**
Bias and 95% limits of agreement for MVPA calculated between pairs of ActiGraph® methods.

| Axis | | VT | | | VM | |
|---|---|---|---|---|---|---|
| | acronym | AG1952 | AG2000 | AG2020 | AG56 | AG2690 |
| VT | AG2000 | 10 ± 10 (−9 to 30) | | | | |
| | AG2020 | −2 ± 2 (−6 to 2) | −12 ± 10 (−32 to 7) | | | |
| VM | AG56 | 28 ± 21 (−12 to 69) | 18 ± 16 (−13 to 50) | 30 ± 20 (−10 to 70) | | |
| | AG2690 | 21 ± 19 (−16 to 57) | 11 ± 19 (−27 to 49) | 23 ± 20 (−15 to 61) | −8 ± 16 (−38 to 23) | |
| | AG3208 | 1 ± 14 (−27 to 29) | −9 ± 16 (−40 to 22) | 3 ± 15 (−25 to 32) | −27 ± 14 (−54 to 0) | −20 ± 10 (−40 to 1) |

VT: vertical axis; VM: vector magnitude. Data presented as bias (row - column) mean ± standard deviation (95% limits of agreement), data reported in minutes.

**Table 4**
Bias and 95% limits of agreement for MVPA calculated between pairs of activPAL® methods.

| Output | | METs | cadence | activity counts |
|---|---|---|---|---|
| | acronym | aP3 | aP100 | aP1418 |
| cadence | aP100 | −33 ± 19 (−72 to 5) | | |
| activity counts | aP1418 | 52 ± 27 (−1 to 105) | 85 ± 42 (3 to 168) | |
| | aP2997 | 0 ± 15 (−28 to 29) | 34 ± 25 (−16 to 83) | −52 ± 24 (−98 to −6) |

METs: metabolic equivalents. Data presented as bias (row - column) mean ± standard deviation (95% limits of agreement), data reported in minutes.

example, the pair of aP3 and aP100 had a bias of −33±19 min (95% LOA −72 to 5 min). The pair of aP3 and aP2997 had a zero bias (Fig. 1f), but the 95% LOA were large (range ~60 min).

## 4. Discussion

The current study aimed to examine the agreement in measuring MVPA for adults in a free-living environment between two objective monitors, the ActiGraph® and the activPAL®, using pre-existing published methods to calculate MVPA. The ActiGraph® monitor is commonly used to measure MVPA in adults, and the study therefore aimed to assess whether the activPAL® was also an acceptable tool to assess MVPA. Across the ten methods tested, reported MVPA varied considerably, between 60 and 145 min (±40% of the mid-value). As this was an agreement study without a criterion measure, the actual value of MVPA was not known. In general, the activPAL® cadence method (aP100) underestimated MVPA compared to ActiGraph® methods, but had the smallest bias (−16 min), and 95% LOA (<90 min). Comparison with individual methods could be smaller, for example the bias of the aP100 method was −6 min compared with the popular 'Freedson' cut-points (AG1952). A bias of 16 min between methods can be considered large in terms of the amount of MVPA performed in a day, where achieving 22 min of MVPA each day would be sufficient to meet many PA guidelines. However, this level of agreement was also similar to that between different pre-existing ActiGraph® methods. The use of activPAL® to measure time spent in MVPA can therefore be placed within the same conversation as the relative merits of the different ActiGraph® methods for measuring MVPA.

The embedded MET equation in the activPAL® has been shown to both significantly under- and over-estimate actual energy expenditure in METs in adolescent and young adult females [26], and in young children [27]. However, while the value of the embedded activPAL® MET algorithm might not provide an accurate estimate of energy expenditure, it can be used in adults to accurately categorise activity into SB and MVPA using the embedded METs estimates [22]. It should be noted, however, that the value that the embedded MET equation ascribed to standing was changed (from 1.4 to 1.5 METs) from the default settings within the activPAL® software. It is possible that further refinement of the internal algorithm may improve MET classification. Indeed, Harrington *et al.* [26] found that the acceleration count output of the activPAL® was better correlated to energy expenditure ($r = 0.76$) than cadence ($r = 0.59$). However, in the current study, the cut-point for MVPA derived from counts (in adolescent females, aP2997) did not perform better than the method based on the embedded MET algorithm (aP3).

The embedded MET algorithm method (aP3), when assessing MVPA, is based on the cadence of activity categorised as walking, with 3METs defined as being at a cadence of 74 steps/minute. As the aP100 method consistently underestimated, and the aP3 consistently overestimated, time spent in MVPA compared to the ActiGraph® it is possible that defining a value between 74 and 100 steps/min to represent MVPA would improve the calculation of time spent in MVPA. In both methods, only periods of walking could be characterised as MVPA. Any MVPA undertaken at other times, for example when standing or seated, would not be picked up. However, it is unclear whether there would be sufficient hip acceleration for the ActiGraph® to classify such periods as MVPA. In the current study, such activity is likely to have been missed by both monitors.

The predominant predictor of time spent in MVPA for each ActiGraph® method appeared to be the axes used to generate counts (vertical axis or vector magnitude). The exception was the AG3208 VM-based method, which performed more like the VT methods than the other VM methods. One possible explanation for this is that this method was developed using artificial neural networks, as opposed to the more standard statistical methods of linear regression or optimising receiver operating characteristic curves used for all the other ActiGraph® methods. Except for development population, other aspects of the studies to derive cut-points were similar (e.g. oxygen consumption used as the criterion measure; walking and running always included in the protocol).

Many methods, for both activPAL® and ActiGraph® monitors, were developed on data from a uni-axial monitor. In the current study, only tri-axial monitors were used, and it was assumed during data processing that using the specified single axis value in the tri-axial monitor was equivalent to using a uni-axial monitor. However, any differences in the sensing units and data processing hardware between monitor models might affect the validity of that assumption. For activPAL®, no studies have compared the value of the acceleration output between uni-axial and tri-axial models. It is therefore unclear if any differences in value of the *x*-axis between the monitors exist, and thus whether the use of

these activPAL® cut-points developed using activity counts in a uniaxial activPAL® are valid for a tri-axial activPAL®. However, the agreement in classification of activity (sit, stand, walk) between uni-axial and tri-axial activPAL® monitors, was good for standardised activities for children, adults [39] and older adults [40], but lower during simulated activities of daily living (ADL) for children and adults [39]. It is therefore possible that those differences in the value of x-axis acceleration might arise in a free-living environment, affecting the results of the current study.

All the VT cut-points of the ActiGraph® were developed on uni-axial versions of the monitor. In adults, there were no significant differences in vertical axis counts between a GT1M uniaxial ActiGraph® and a GT3X tri-axial ActiGraph®, when walking and running on a treadmill [41]. Bland and Altman analysis indicated a bias of 50 counts per minute between the monitors with 95% LOA of approximately ±700 counts per minute. In children, using a 1 s epoch, agreement in vertical axis was good for static postures and walking, but was significantly higher in the GT3X for running and Wii boxing tasks [42]. For walking and running-based MVPA in adults, then, it seems reasonable to use the ActiGraph® axes interchangeably.

Many studies have been conducted to examine the agreement between ActiGraph® and activPAL® in classifying SB [16,30,31], using activPAL® as the reference standard, with the aim of identifying the most comparable ActiGraph® cut-points to measure SB. It is, however, clear that the ActiGraph® does not adequately assess postural sitting, due to the nature of measuring acceleration at the hip [17,20,28]. Other than a lack of previous research interest, there is no equivalent reason to assume that the activPAL® cannot adequately measure MVPA. Therefore, a key strength of the current study was that it investigated a potentially realistic option for using a single monitor to adequately assess both MVPA and SB.

The study also had several weaknesses. The study had a small sample size drawn only from a higher education setting, and therefore may not be generalisable to a wider population. However, the use of concurrent measurement meant that comparison was made between monitors on the actual activity of the participant, regardless of how typical. Another weakness was the lack of a criterion measure, so there was no knowledge of the actual MVPA of participants in the study. This means that all assessment of agreement between methods was relative and not absolute. However, there are limited options to provide an adequate criterion method for free-living activity over a longer period (e.g. a day); indirect calorimetry cannot be comfortably worn for extended periods, and direct observation is potentially intrusive and time consuming to achieve. In a study aiming to assess the potential of one monitor method to agree with another established monitor, concurrent measurement is an acceptable methodology.

A particular weakness of the current study was the inclusion, in a study with adult participants, of methods to derive MVPA developed for younger populations (adolescents and children). This decision was driven by the lack of cut-points using activity count developed for the activPAL® for adults, coupled with the desire to assess the potential utility of such methods for the calculation of MVPA. It is unclear how different an adolescent population might be from the relatively young adults who participated in the current study, although the development of the adolescent cut-point including only female participants is an additional limitation. However, in the current study, this method (aP2997) performed relatively similarly to one of the other activPAL® methods derived for adults (aP3). It is clear that the methods designed for children resulted in higher values of time spent in MVPA. In particular, the method derived for the activPAL® for 4–6 year olds resulted in a value of MVPA 50 min greater than any other outcome (145 min vs 94 min). Further research is required to elucidate how different an activPAL® cut-points using activity count developed for adults would be, and how well it would agree with ActiGraph® assessments of MVPA.

## 5. Conclusion

The agreement of different methods of calculating MVPA (four using the activPAL® monitor and six using the ActiGraph® monitor) were assessed on concurrently measured free-living data in adults. Using a cadence of 100 steps/minute underestimated MVPA compared to ActiGraph® methods, and had the lowest aggregate bias (−16 min). Pairs of methods could have smaller bias, for example, the cadence method (aP100) and the 'Freedson' cut-points (AG1952) had a bias of −6 min. Other activPAL® methods, based on acceleration counts and the embedded MET algorithm, overestimated MVPA compared to the Actigraph®. However, the study was limited by the lack of activPAL® acceleration count methods developed specifically for an adult population. The current study found that the comparisons between measuring MVPA using the activPAL® were in the same range as comparisons between different ActiGraph® cut-points. As previous research has established that the activPAL® is preferable to the ActiGraph for the measurement of SB, these results showing its comparability with ActiGraph® for measuring MVPA, suggest that the activPAL® may be suitable to use as a single monitor to adequately measure both SB and MVPA.

## Declaration of Competing Interests

LFRL none, PMD has previously received grant income from PAL technologies outside of the submitted work.

## Acknowledgments

We are grateful to Dr Stefan Teufl, who collected this data alongside that for (part of) his PhD. This data analysis was conducted as part of the Masters studies of LFR Lee. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

## Ethical approval

This study was conducted in accordance with the Declaration of Helsinki. Ethical approval was provided by the School of Health at Glasgow Caledonian University ethics committee (reference number HLS12/50), and informed consent was obtained from all participants before data collection.

## Supplementary material

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.medengphy.2019.09.018.

## References

[1] Hallal PC, Anderson LB, Bull FC, Guthold R, Haskell W, Ekelund U. Global physical activity levels: surveillance progress, pitfalls, and prospects. Lancet 2012;380(9838):247–57.
[2] World Health Organization. Global health risks: mortality and burden of disease attributable to selected major risks, Geneva: WHO press; 2009. Available at: http://www.who.int/healthinfo/global_burden_disease/GlobalHealthRisks_report_full.pdf Accessed 13 November 2016.
[3] World Health Organization: Physical activity: fact sheet; 2016. Available at: http://www.who.int/mediacentre/factsheets/fs385/en/. Accessed 13 November 2016.
[4] Pratt M, Norris J, Lobelo F, Roux L, Wang G. The cost of physical activity: moving into the 21st century. Br J Sports Med 2014;48(3):171–3.
[5] World Health Organization: What is moderate-intensity and vigorous-intensity physical activity? Available at: http://www.who.int/dietphysicalactivity/physical_activity_intensity/en/. Accessed 13 November 2016.

[6] Drenowatz C, Prasad VK, Hand GA, Shook RP, Blair SN. Effects of moderate and vigorous physical activity on fitness and body composition. J Behav Med 2016;39(4):624–32.
[7] Tremblay MS, Aubert S, Barnes JD, Saunders TJ, Carson V, Latimer-Cheung AE, et al. Sedentary behavior research network (SBRN)–Terminology consensus project process and outcome. Int J Behav Nutr Phys Act 2017;14:75.
[8] Biswas A, Oh PI, Faulkner GE, Bajaj RR, Silver MA, Mitchell MS, et al. Sedentary time and its association with risk for disease incidence, mortality, and hospitalization in adults: a systematic review and meta-analysis. Ann Intern Med 2015;162(2):123–32.
[9] Ekelund U, Steene-Johannessen J, Brown WJ, Fagerland MW, Owen L, Powell KE, et al. Does physical activity attenuate, or even eliminate, the detrimental association of sitting time with mortality? A harmonised meta–analysis of data from more than 1 million men and women. Lancet 2016;388(10051):1302–10.
[10] Chastin SFM, Dontje ML, Skelton DA, Čukić I, Shaw RJ, Gill JMR, et al. Systematic comparative validation of self-report measures of sedentary time against an objective measure of postural sitting (activPAL®). Int J Behav Nutr Phys Act 2018;15:21.
[11] Rosenberger ME, Buman MP, Haskell WL, McConnell MV, Carstensen LL. Twenty-four hours of sleep, sedentary behavior, and physical activity with nine wearable devices. Med Sci Sports Exerc 2016;48(3):457–65.
[12] Steeves JA, Bowles HR, McClain JJ, Dodd KW, Brychta RJ, Wang J, et al. Ability of thigh-worn actigraph® and activPAL® monitors to classify posture and motion. Med Sci Sports Exerc 2015;47(5):652–9.
[13] John D, Freedson P. Actigraph® and actical physical activity monitors: a peek under the hood. Med Sci Sports Exerc 2013;44(Suppl 1):S86–9.
[14] Rothney MP, Apker GA, Song Y, Chen KY. Comparing the performance of three generations of actigraph® accelerometers. J Appl Physiol (1985) 2008;105(4):1091–7.
[15] Kim Y, Beets MW, Welk GJ. Everything you wanted to know about selecting the "right" actigraph® accelerometer cut-points for youth, but…: a systematic review. J Sci Med Sport 2012;15(4):311–21.
[16] Aguilar-Farías N, Brown WJ, Peeters GM. ActiGraph GT3X+ cut-points for identifying sedentary behaviour in older adults in free-living environments. J Sci Med Sport 2014;17(3):293–9.
[17] Crouter SE, Clowers KG, Bassett DR. A novel method for using accelerometer data to predict energy expenditure. J Appl Physiol 2006;100(4):1324–31.
[18] Granat MH. Event-based analysis of free-living behaviour. Physiol Meas 2012;33(Suppl 1):1785–800.
[19] Sellers C, Dall P, Grant M, Stansfield B. Validity and reliability of the activPAL3 for measuring posture and stepping in adults and young people. Gait Posture 2016;43:42–7.
[20] Kozey-Keadle S, Libertine A, Lyden K, Staudenmayer J, Freedson PS. Validation of wearable monitors for assessing sedentary behaviour. Med Sci Sports Exerc 2011;43(8):1561–7.
[21] Godfrey A, Culhane KM, Lyons GM. Comparison of the performance of the activPAL™ professional physical activity logger to a discrete accelerometer-based activity monitor. Med Eng Phys 2007;29(8):930–4.
[22] Lyden K, Kozey-Keadle S, Staudenmayer J, Freedson PS. The activPAL™ accurately classifies activity intensity categories in healthy adults. Med Sci Sports Exerc 2017;49(5):1022–8.
[23] Dall PM, Ellis SLH, Ellis BM, Grant PM, Colyer A, Gee NR, et al. The influence of dog ownership on objective measures of free-living physical activity and sedentary behaviour in community-dwelling older adults: a longitudinal case–controlled study. BMC Public Health 2017;17(1):496.
[24] Dowd KP, Harrington DM, Donnelly AE. Criterion and concurrent validity of the activPAL™ professional physical activity monitor in adolescent females. PLoS One 2012;7:10.
[25] Chastin SFM, Palarea-Albaladejo J, Dontje ML, Skelton DA. Combined effects of time spent in physical activity, sedentary behaviors and sleep on obesity and cardio-metabolic health markers: a novel compositional data analysis approach. PLoS One 2015;10(10):e0139984.
[26] Harrington DM, Welk GJ, Donnelly AE. Validation of met estimates and step measurement using the activpal® physical activity logger. J Sports Sci 2011;29(6):627–33.
[27] Janssen X, Cliff DP, Reilly JJ, Hinkley T, Jones RA, Batterham M, et al. Validation and calibration of the activPAL™ for estimating METs and physical activity in 4-6 year olds. J Sci Med Spor 2014;17(6):602–6.
[28] Kim Y, Barry VW, Kang M. Validation of the actigraph® GT3X and activPAL® accelerometers for the assessment of sedentary behavior. Meas Phys Educ Exerc Sci 2015;19(3):125–37.
[29] Ryde GC, Gilson ND, Suppini A, Brown WJ. Validation of a novel, objective measure of occupational sitting. J Occup Health 2012;54(5):383–6.
[30] Ridgers ND, Salmon J, Ridley K, O'Connell E, Arundell L, Timperio A. Agreement between activPAL® and actigraph® for assessing children's sedentary time. Int J Behav Nutr Phys Act 2012;9:15.
[31] Martin A, McNeill M, Penpraze V, Dall P, Granat M, Paton JY, et al. Objective measurement of habitual sedentary behavior in pre-school children: comparison of activPAL® with actigraph® monitors. Pediatr Exerc Sci 2011;23(4):468–76.
[32] PAL technologies: activPAL brochure. Available at: http://www.paltech.plus.com/activPALBrochure.1001.40417.1.6.pdf. Accessed 15 November 2016.
[33] PALtechnologies. ActivPAL Operating guide 2010. Available at: http://www.paltechnologies.com/. Accessed 14 June 2017.
[34] R. Development Core Team. R: a language and environment for statistical computing. Available at https://cran.r-project.org/doc/manuals/r-release/fullrefman.pdf. Accessed 14 June 2017.
[35] Harrington DM, Dowd KP, Tudor-Locke C, Donnelly AE. A steps/minute value for moderate intensity physical activity in adolescent females. Pediatr Exerc Sci 2012;24(3):399–408.
[36] Marshall SJ, Levy SS, Tudor-Locke CE, Kolkhorst FW, Wooten KM, Ji M, et al. Translating physical activity recommendations into a pedometer-based step goal 3000 steps in 30 min. Am J PrevMed 2009;36(5):410–15.
[37] Abel M, Hannon J, Mullineaux D, Beighle A. Determination of step rate thresholds corresponding to physical activity intensity classifications in adults. J Phys Act Health 2011;8(1):45–51.
[38] Kelly LA, McMillan DGE, Anderson A, Fippinger M, Fillerup G, Rider J. Validity of actigraphs® uniaxial and triaxial accelerometers for assessment of physical activity in adults in laboratory conditions. BMC Med Phys 2013;13(1):5.
[39] Sellers C, Dall P, Grant M, Stansfield B. Agreement of the activPAL3® and activPAL® for characterising posture and stepping in adults and children. Gait Posture 2016;48:209–14.
[40] Klenk J, Büchele G, Lindemann U, Kaufmann S, Peter R, Laszlo R, et al. Concurrent validity of activPAL® and activPAL3v accelerometers in older adults. J Aging Phys Act 2016;24(3):444–50.
[41] Sasaki JE, John D, Freedson PS. Validation and comparison of actigraph® activity monitors. J Sci Med Sport 2011;14(5):411–16.
[42] Hänggi JM, Phillips LR, Rowlands AV. Validation of the GT3X actigraph® in children and comparison with the GT1M actigraph®. J Sci Med Sport 2013;16(1):40–4.
[43] Freedson PS, Melanson E, Sirard J. Calibration of the computer science and applications, inc. accelerometer. Med Sci Sports Exerc 1998;30(5):777–81.
[44] Morton KL, Corder K, Suhrcke M, Harrison F, Jones AP, van Sluijs EMF, et al. School polices, programmes and facilities, and objectively measured sedentary time, lpa and MVPA: associations in secondary school and over the transition from primary to secondary school. Int J Behav Nutr Phys Act 2016;13:54.
[45] Troiano RP, Berrigan D, Dodd KW, Mâsse LC, Tilert T, McDowell, et al. Physical activity in the united states measured by accelerometer. Med Sci Sports Exerc 2008;40(1):181–8.
[46] Santos-Lozano A, Santín-Medeiros F, Cardon G, Torres-Luque G, Bailón R, Bergmeir C, et al. Actigraph® GT3X: validation and determination of physical activity intensity cut points. Int J Sports Med 2013;34(11):975–82.